Cost-Related Nonadherence (CRN) to Medication by Kassel, Jessica
Cost-related Nonadherence (CRN) to Medication
Jessica Kassel
Fontbonne University
Introduction
• Cost-related nonadherence (CRN) to medication is a growing health-care 
issue in the United States. 
• CRN to medication is usually defined as skipping doses, taking less 
medication than prescribed, and/or delaying medication use due to costs. 
• Among 11 developed countries, the United States’ CRN to medication is the 
highest at 17 percent. 
• When individuals experience CRN to medication, they become vulnerable to 
additional adverse health outcomes, which may lead to more frequent 
hospitalizations, emergency department visits, and, in the worst-case 
scenario, death. 
• Mitigation of CRN to medicine may lead to a reduction in patients’ use of 
health-care services by improving patients’ overall health and preventing 
hospital admissions. 
Vulnerable Populations
• Patients with chronic conditions, including cancer survivors, are most 
vulnerable to CRN to medication.
• This population requires extensive medical interventions, including 
medicine. 
• Higher-out-of-pocket expenses due to multiple medications and having a 
lower income can increase risk of CRN to medication.
Declining Affordability of Medicine
• The rising cost of medication is a chief factor contributing to financial 
stress within the vulnerable population.
• The vulnerable population can be exposed to even higher medication costs 
if the individuals have limited to no prescription coverage or higher-out-of-
pocket costs for prescriptions.
• Having a high-deductible health plan is also associated with CRN to 
medication.
Effect of Government Policies
• Changes in policy can both positively and negatively affect CRN to 
medication. 
• The Affordable Care Act gave more individuals access to prescription 
coverage.
• After the implementation of Medicare Part D in 2006, the percentage of 
seniors not filling prescriptions dropped from 5.4% to 3.6%.
• A coverage gap exists in the Medicare Part D policy. This can promote CRN 
to medication.
Complex Medication Supply Chain
• The medication supply chain can drive pricing for medications, as well as the 
types of medications covered within an insurance plan.
• Tiering of drug formularies and utilization management techniques (prior 
authorizations) can increase CRN to medication.
Interventions
• Public health initiatives, such as the federal Supplemental Nutrition 
Assistance Program (SNAP) can positively impact the population most 
vulnerable to CRN to medication.
• SNAP reduces participants’ food costs and may free up more money for 
medication purchases.
Advocacy Efforts
• Efforts focused on CRN to insulin among individuals with type 1 or type 2 
diabetes. These individuals must take their insulin every day or face serious 
health complications, including coma and death. 
• Became an American Diabetes Association (ADA) diabetes advocate.
• Watched several advocacy webinars offered through the ADA.
• Promoted several insulin cost-reduction programs through personal social 
media account.
• Wrote to my federal and state legislators regarding several pending insulin 
cost-reduction bills.
• Sen. Roy Blunt positively responded to my letter. Going forward, I hope to 
meet with him in person.
Call to Action
• With the growing economic fallout from COVID-19, efforts to reduce the 
cost of insulin are more important than ever.
• In April 2020, two of the three insulin manufacturers made decisions to 
further reduce the cost of their insulin products.
• More work needs to be done! Go to 
https://www.diabetes.org/advocacy/platform to inform your federal 
legislators of the importance of the Insulin Price Reduction Act.
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